Pharmaron Beijing
Pharmaron Beijing Co., Ltd., commonly referred to as Pharmaron, is a leading contract research organisation (CRO) headquartered in Beijing, China. Established in 2004, the company has rapidly expanded its operational footprint across major regions, including North America and Europe, positioning itself as a key player in the pharmaceutical and biotechnology sectors. Pharmaron offers a comprehensive suite of services, including drug discovery, development, and manufacturing, with a focus on small molecules and biologics. Its unique integration of advanced technologies and scientific expertise enables clients to accelerate their drug development processes. Notably, Pharmaron has achieved significant milestones, such as successful collaborations with global pharmaceutical companies, solidifying its reputation for excellence in the industry. With a commitment to innovation and quality, Pharmaron continues to enhance its market position as a trusted partner in the life sciences arena.
DitchCarbon Score
How does Pharmaron Beijing's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pharmaron Beijing's score of 47 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaron Beijing's reported carbon emissions
In 2023, Pharmaron Beijing reported total greenhouse gas emissions of approximately 251,396,910 kg CO2e, comprising 34,755,680 kg CO2e from Scope 1, 216,740,300 kg CO2e from Scope 2, and 395,142,930 kg CO2e from Scope 3 emissions. This data highlights the company's significant carbon footprint across its operations. Pharmaron has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across its entire value chain by 2050. The company has established near-term targets to reduce absolute Scope 1 and 2 emissions by 54.6% by 2033, using 2023 as the baseline year. Additionally, it aims to decrease Scope 3 emissions by 61.07% per million CNY value added within the same timeframe. For long-term goals, Pharmaron plans to achieve a 90% reduction in absolute Scope 1 and 2 emissions by 2050, based on a 2021 baseline, and a 97% reduction in Scope 3 emissions per million CNY value added by the same year. These targets align with the Science Based Targets initiative (SBTi) and reflect the company's commitment to addressing climate change within the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 48,007,050 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 267,941,280 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pharmaron Beijing is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
